Bayer マネジメント

マネジメント基準チェック /14

We currently do not have sufficient information about the CEO.

主要情報

Bill Anderson

最高経営責任者

€11.8m

報酬総額

CEO給与比率	14.3%
CEO在任期間	1.6yrs
CEOの所有権	n/a
経営陣の平均在職期間	1.3yrs
取締役会の平均在任期間	7yrs

経営陣の近況

Recent updates

CEO報酬分析

Bayer の収益と比較して、Bill Anderson の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Jun 30 2024	n/a	n/a	-€1b
Mar 31 2024	n/a	n/a	-€3b
Dec 31 2023	€12m	€2m	-€3b

報酬と市場: Bill's total compensation ($USD12.88M) is above average for companies of similar size in the Polish market ($USD4.35M).

報酬と収益: Insufficient data to compare Bill's compensation with company performance.

CEO（最高経営責任者

Bill Anderson (58 yo)

1.6yrs

在職期間

€11,804,104

報酬

Mr. William N. Anderson, also known as Bill, is Member of Management Board of Bayer Aktiengesellschaft from April 1, 2023 and also serves as its Chairman of the Management Board and Chief Executive Officer...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
William Anderson	Chairman of the Management Board & CEO	1.6yrs	€11.80m	データなし
Wolfgang Nickl	CFO & Member of Management Board	6.6yrs	€3.42m	データなし
Stefan Oelrich	Head of the Pharmaceuticals Division & Member of the Board of Management	6yrs	€3.43m	データなし
Rodrigo Santos	Member of Management Board & President of the Crop Science Division	2.8yrs	€3.65m	データなし
Heike Prinz	Chief Talent Officer	1.2yrs	€2.53m	データなし
Julio Triana	Member of Management Board & President of Consumer Health Division	less than a year	データなし	データなし
Sebastian Guth	Chief Operating Officer	less than a year	データなし	データなし
Amanda McClerren	Chief Information Officer	less than a year	データなし	データなし
Jost Reinhard	Head of Investor Relations	1.1yrs	データなし	データなし
Thomas Laubert	Head of Law	1.3yrs	データなし	データなし
Michael Preuss	Head of Communications	8.5yrs	データなし	データなし
Bernd-Peter Bier	Head of Group Finance	no data	データなし	データなし

1.3yrs

平均在職期間

56yo

平均年齢

経験豊富な経営陣: BAY's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.

取締役

名称	ポジション	在職期間	報酬	所有権
Paul M. Achleitner	Member of Supervisory Board	22.6yrs	€225.00k	データなし
Ertharin Cousin	Independent Member of the Supervisory Board	5.1yrs	€270.00k	データなし
Heinz Webers	Employee Representative Member of Supervisory Board	2.6yrs	€205.00k	データなし
Simone Bagel-Trah	Independent Member of Supervisory Board	10.6yrs	€227.00k	データなし
Daniel Hartert	Chairman of Executive Board - Bayer Business Services	no data	データなし	データなし
Lori Schechter	Independent Supervisory Board Member	less than a year	データなし	データなし
Horst Baier	Independent Member of Supervisory Board	4.6yrs	€333.00k	データなし
Heike Hausfeld	Vice Chairwoman of Supervisory Board	7.6yrs	€346.00k	データなし
André van Broich	Member of Supervisory Board	12.6yrs	€271.00k	データなし
Otmar Wiestler	Independent Member of Supervisory Board	10.1yrs	€237.00k	データなし
Norbert Winkeljohann	Independent Chairman of Supervisory Board	6.5yrs	€509.00k	データなし
Gunter Hilken	Chairman of Executive Board - Currenta	no data	データなし	データなし

7.0yrs

平均在職期間

66.5yo

平均年齢

経験豊富なボード: BAY's board of directors are considered experienced (7 years average tenure).

Bayer マネジメント

マネジメント 基準チェック /14

主要情報

経営陣の近況

Bayer Appoints Sue Ann Pentecost as Head of U.S. Pharmaceutical Communications

Bayer Aktiengesellschaft, Annual General Meeting, Apr 25, 2025

Bayer Aktiengesellschaft, Annual General Meeting, Apr 26, 2024

Bayer Announces Key Leadership Changes for its Crop Science Division

Bayer AG Announces Management Changes

Recent updates

Bayer and Liveo Research Launches Blister Packaging with Improved Environmental Footprint

Bayer Submits Application for Third Indication of Darolutamide in the EU

U.S. Food and Drug Administration Accepts New Drug Application for Bayer's Elinzanetant

Bayer Ag and BlueRock Therapeutics LP Announces Positive 24-Month Data from exPDite

Bayer Submits Application to U.S. FDA for Third Indication of darolutamide

New minor risk - Share price stability

Bayer to Unveil New Data from its Phase III OASIS 3 Long-Term Study of Elinzanetant in the Treatment of Vasomotor Symptoms Associated with Menopause

Bayer Announces Late-Breaking KERENDIA® (finerenone) Investigational Data Presented

Bayer to Present Phase III Kerendia (Finerenone) Data

New minor risk - Share price stability

Second quarter 2024 earnings released: €0.03 loss per share (vs €1.92 loss in 2Q 2023)

Bayer Announces Primary Endpoint Achieved in Phase III FINEARTS-HF Cardiovascular Outcomes Study Investigating KERENDIA in Patients with Heart Failure with Mildly Reduced or Preserved Ejection Fraction

Bayer Submits New Drug Application to U.S. FDA for Elinzanetant for the Treatment of Moderate to Severe Vasomotor Symptoms Associated With Menopause

Bayer Presents Latest Data from Oncology Portfolio at 2024 ASCO Annual Meeting

Bayer Starts Phase I Study with Novel Targeted Radionuclide Therapy 225Ac-Psma-Trillium in Advanced Metastatic Prostate Cancer

First quarter 2024 earnings released: EPS: €2.04 (vs €2.22 in 1Q 2023)

Bayer to Unveil Late-Breaking Data from Phase Iii Oasis 1 and 2 for Elinzanetant in the Treatment of Vasomotor Symptoms Associated with Menopause

Bayer AG and Asklepios BioPharmaceutical, Inc Presents Results from the 18-Month Phase Ib Clinical Trial for AB-1005

Bayer Appoints Sue Ann Pentecost as Head of U.S. Pharmaceutical Communications

Bayer Announces Positive Topline Results from Phase III Long-Term Study Oasis 3 Support Submits for Marketing Authorization for Bayer's Elinzanetant

Bayer Aktiengesellschaft, Annual General Meeting, Apr 25, 2025

Full year 2023 earnings released: €2.99 loss per share (vs €4.22 profit in FY 2022)

Bayer Announces Start of Phase II Clinical Trial with BAY3018250

Bayer Aktiengesellschaft, Annual General Meeting, Apr 26, 2024

Now 23% undervalued after recent price drop

Bayer Aktiengesellschaft to Report Q4, 2023 Results on Mar 05, 2024

Bayer Announces Key Leadership Changes for its Crop Science Division

Bayer Starts Phase II Study Nirvana to Evaluate Elinzanetant in Women with Sleep Disruptments Associated with Menopause

Williams Hart & Boundas Wins Against Bayer

Now 20% undervalued after recent price drop

Now 23% undervalued after recent price drop

Bayer Announces OCEANIC-AF Study Starts Early Due to Lack of Efficacy

Bayer Issues Voluntary Recall Nationwide of VITRAKVI® (larotrectinib) Oral Solution 20 mg/mL Due to Presence of Microbial Contamination

Bayer Provides Update on Aliqopa (Copanlisib)

Third quarter 2023 earnings released: €4.66 loss per share (vs €0.56 profit in 3Q 2022)

Bayer Announces Pharmacodynamic Data on Kerendia

Bayer Aktiengesellschaft to Report Q3, 2023 Results on Nov 08, 2023

Bayer to Present Latest Real-World Evidence of Menopausal Symptoms and Their Treatment

Bayer Aktiengesellschaft (XTRA:BAYN) signed an agreement to acquire strawberry pipeline and commercial portfolio from NIAB.

Bayer AG and BlueRock Therapeutics LP Announces Details of the Positive Data from the Phase I Clinical Trial for Bemdaneprocel (BRT-DA01), A Stem Cell Derived Investigational Therapy for Treating Parkinson's Disease

Bayer AG and Bluerock Therapeutics LP Announces Results of the Positive Data from the Phase I Clinical Trial for Bemdaneprocel (Brt-Da01)

Bayer AG Announces Management Changes

New minor risk - Profit margin trend

Second quarter 2023 earnings released: €1.92 loss per share (vs €0.30 loss in 2Q 2022)

Bayer Aktiengesellschaft Provides Earnings Guidance for Full-Year 2023

Industrias Químicas del Valles S.A. reached an agreement to acquire Bayer's phytosanitary products factory in Valencia from Bayer Aktiengesellschaft (XTRA:BAYN).

CEO報酬分析

CEO（最高経営責任者

在職期間

報酬

リーダーシップ・チーム

平均在職期間

平均年齢

取締役

平均在職期間

平均年齢

マネジメント基準チェック /14